Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers
Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers
复制标题
DOI：
10.1016/j.ygyno.2009.03.017
复制
发表时间：
2009-07-01
影响因子：
4.7
通讯作者：
Tamaya, Teruhiko
中科院分区：
文献类型：
--
作者：
Alam, Syed Mahfuzul;Fujimoto, Jiro;Tamaya, Teruhiko
Objective.受体EphB 4和相应的配体ephrinB 2有助于各种人类肿瘤中的肿瘤生长。这促使我们研究EphB 4和ephrinB 2在子宫颈癌中的表达和定位，以分析EphB 4/ephrinB 2在临床背景下的功能。采用免疫组化和实时荧光定量PCR方法检测62例宫颈癌组织中EphB 4和ephrinB 2的表达。分析患者的生存率和36个月的生存率。EphB 4和ephrinB 2主要定位于所有病例的宫颈癌细胞中。EphB 4和ephrinB 2的组织学评分和mRNA水平均随宫颈癌临床分期（I < II < III + IV，p < 0.001）而显著增加。肿瘤大小与组织学评分及EphB 4和ephrinB 2 mRNA水平显著相关。EphB 4和ephrinB 2的组织学评分和mRNA水平与淋巴结转移有关，但与组织病理学类型无关。EphB 4和ephrinB 2高表达的31例患者的36个月生存率较低（分别为31%和19%），而EphB 4和ephrinB 2低表达的31例患者的36个月生存率显著较高（分别为72%和73%）。EphB 4和ephrinB 2的共表达随着基于临床分期、淋巴结转移、肿瘤大小的疾病进展以及患者预后差而增加。因此，EphB 4/ephrinB 2的表达可能对肿瘤的进展起作用，Eph/ephrin系统的共表达可能促进肿瘤的进展，导致生存率降低，因此可以被认为是宫颈癌原发肿瘤的一种新的预后指标。(C)2009 Elsevier Inc. All rights reserved.
Objective. Receptor EphB4 and the corresponding ligand ephrinB2 contribute to tumor growth in various human tumors. This prompted us to study the expression and localization of EphB4 and ephrinB2 in uterine cervical cancers to analyze the EphB4/ephrinB2 functions against clinical backgrounds.Methods. Immunohistochemistry and real-time RT-PCR have been done to determine the histoscores and mRNA levels of EphB4 and ephrinB2, respectively, in sixty-two uterine cervical cancer tissue samples. Patient prognoses were analyzed with a 36-month survival rate.Results. The localization of EphB4 and ephrinB2 was dominantly in the cancer cells of uterine cervical cancers of all cases given. Both the histoscores and mRNA levels of EphB4 and ephrinB2 significantly increased with clinical stages (I < II < III + IV, p < 0.001) in uterine cervical cancers. The tumor sizes significantly correlated with the histoscore and mRNA levels of EphB4 and ephrinB2. There were significant differences in histoscores and mRNA levels of EphB4 and ephrinB2 in accordance with lymph node metastasis, but not according to histopathological types. The 36-month survival rates of the 31 patients with high EphB4 and ephrinB2 expression were poor (31% and 19%, respectively), while survival rates for the other 31 patients with low EphB4 and ephrinB2 expression were significantly higher (72% and 73%, respectively).Conclusion. Coexpression of EphB4 and ephrinB2 increased with the disease advancement based on clinical stage, lymph node metastasis, tumor size and with poor patient prognoses. Therefore, EphB4/ephrinB2 expression might work on tumor advancement and coexpression of the Eph/ephrin system may potentiate tumor progression leading to poor survival, thus can be recognized as a novel prognostic indicator in the primary tumors of uterine cervical cancers. (C) 2009 Elsevier Inc. All rights reserved.